KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases. The genetic landscape of KRAS wild type PDAC can be divided into three categories. The first is represented by tumors with an...

Descripción completa

Detalles Bibliográficos
Autores principales: Luchini, Claudio, Paolino, Gaetano, Mattiolo, Paola, Piredda, Maria L., Cavaliere, Alessandro, Gaule, Marina, Melisi, Davide, Salvia, Roberto, Malleo, Giuseppe, Shin, Jae Il, Cargnin, Sarah, Terrazzino, Salvatore, Lawlor, Rita T., Milella, Michele, Scarpa, Aldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594413/
https://www.ncbi.nlm.nih.gov/pubmed/33115526
http://dx.doi.org/10.1186/s13046-020-01732-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594413/
https://www.ncbi.nlm.nih.gov/pubmed/33115526
http://dx.doi.org/10.1186/s13046-020-01732-6

Ejemplares similares